Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE-AA2: Deuruxolitinib in Moderate to Severe Alopecia Areata
NCT04797650Phase 3Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of deuruxolitinib in alopecia areata (3 arms), sponsored by Concert Pharmaceuticals. Primary endpoint: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at 24 weeks. Started Jun 2021; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04797650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797650.